The on-going long-lasting trials using anti-tau antibodies for PSP patients might therefore be biased by the incorrect enrollment of Parkinson’s disease (PD) patients manifesting early axial signs. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.